Pegloticase
From SNPedia
Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated. The drug is administered by infusion intravenously.Wikipedia
The FDA and EMA state that pegloticase should not be used in patients who are G6PD-deficient, and that patients at risk for G6PD-deficiency should be screened prior to starting treatment.
| Genotype/Genoset | Diplotype | Gene | Drug Use/Category/Class | Medical Field | Summary | Descriptive Sentence |
|---|---|---|---|---|---|---|
| gs309 | WT/WT | G6PD | Gout | Rheumatology | Normal Response Expected | You do not appear to carry any G6PD mutations linked to an unwanted side effect (hemolytic anemia and methemoglobinemia). |
| gs307 | Carrier | G6PD | Gout | Rheumatology | Use with Caution | You carry a G6PD mutation that might lead to an unwanted side effect (hemolytic anemia and methemoglobinemia) when taking pegloticase; due to variable expression (i.e. in females), enzymatic testing for G6PD activity is advisable. |
| gs308 | G6PD-deficient | G6PD | Gout | Rheumatology | Avoid Use | You carry a G6PD mutation linked to an unwanted side effect (hemolytic anemia and methemoglobinemia) when taking pegloticase; pegloticase should not be prescribed for you according to the FDA. |
